跳到正文

艾尔建

争议事件

以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。

返回词条共 4 条

  1. 2024

    法院允许艾尔建针对Revance的商业秘密主张继续审理

    裁决

    在艾尔建针对竞争对手Revance提起的商业秘密诉讼中,法院驳回了Revance的驳回动议,认为有关获取商业秘密及产品相似性的指控足以支持案件继续审理。这些仍是指控,并非责任认定。

    来源摘录

    • The court inferred use of the trade secrets based on access and similarity.
    • District Judge Eli Richardson disagreed, denying Revance’s motion to dismiss.
  2. 2022

    Teva与Allergan就旧金山阿片类药物诉讼达成和解

    和解

    Teva Pharmaceutical Industries与AbbVie旗下Allergan部门就被指助长旧金山阿片类药物流行一事,达成总额5800万美元的和解。Teva将支付2500万美元并提供价值2000万美元的Narcan,AbbVie将支付1300万美元。Teva与Allergan均未承认有不当行为。

    当事方说明的目的. 解决相关索赔并避免下个月开庭审理。

    品牌回应

    • 否认 — CVS Health Corp, Teva Pharmaceutical Industries Ltd, Abbvie Inc's Allergan unit, and Endo International Plc

      The four companies denied wrongdoing in agreeing to settle.

    来源摘录

    • Neither Teva nor Allergan admitted wrongdoing as part of the settlement
    • Under the deal announced by City Attorney David Chiu, Israel-based Teva will pay $25 million in cash and contribute a $20 million supply of the overdose-reversal drug Narcan. AbbVie will pay $13 million.
    • The four companies denied wrongdoing in agreeing to settle.
  3. 2022

    明尼苏达州等州与 Allergan 达成阿片类药物暂定和解

    和解

    明尼苏达州总检察长 Keith Ellison 宣布,多个州已与 Allergan 达成总额 23.7 亿美元的暂定和解协议,最终条款仍待敲定。Ellison 指称,相关公司将利润置于民众生命之上,造成死亡与伤害。

    来源摘录

    • Friday morning, Minnesota Attorney General Keith Ellison announced multiple states had reached a tentative $2.37 billion agreement with Allergan.
    • Even so, I have and will continue to aggressively hold these companies accountable for the harm they’ve caused in order to protect the people of Minnesota.
    • Drug manufacturer Allergan has agreed to pay Suffolk and Nassau counties and the state of New York up to $200 million for its role in the opioid epidemic.
  4. 2018

    阿片类药物相关诉讼

    艾尔建与其他制药制造商和分销商一起,在美国各州和市政当局就阿片类药物流行提起的诉讼中被点名。诉讼涉及在阿片类药物的制造、营销或分销中的所谓角色;诉讼程序构成了更广泛的全国性阿片类药物诉讼的一部分。